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Summary
Background Current treatment for HIV-infected individuals with renal failure on haemodialysis frequently requires 
complex regimens with multiple pills. A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine, 
and tenofovir alafenamide is approved in Europe, the USA, and in other regions for use in HIV-1-infected individuals 
with mild-to-moderate chronic kidney disease (creatinine clearance 30–69 mL/min). We aimed to assess the safety, 
efficacy, an d ph armacokinetics of  th is re gimen in  HI V-infected ad ults wi th en d-stage re nal di sease on  ch ronic 
haemodialysis.
Methods We did an open-label, single-arm, multicentre, phase 3b trial at 26 outpatient clinics in Austria, France, 
Germany, and the USA. Participants were HIV-1-infected adults with end-stage renal disease (creatinine clearance 
<15 mL/min), on chronic haemodialysis for at least 6 months before screening. Virological suppression (ie, plasma 
HIV-1 RNA <50 copies per mL) on a stable antiretroviral regimen was required for at least 6 months before screening 
with a CD4 count of at least 200 cells per µL. We switched all participants to coformulated elvitegravir 150 mg, cobicistat 
150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once daily, taken after haemodialysis for up to 96 weeks. 
We did assessments at study visits at weeks 2, 4, 8, 12, 24, 36, and 48, and every 12 weeks thereafter up to 96 weeks. The 
primary endpoint was the incidence of treatment-emergent adverse events of grade 3 or higher up to week 48. All 
participants who received at least one dose of study drug were included in the primary analysis. This study is registered 
with ClinicalTrials.gov (NCT02600819) and is closed to new participants. 
Findings Between Feb 1, and Nov 3, 2016, 55 participants were enrolled and received at least one dose of study drug. 
Through week 48, 18 of 55 participants (33%, 95% CI 20–45) had an adverse event of grade 3 or higher on study 
treatment. Treatment-emergent grade 3 or higher adverse events that occurred in more than one participant included 
anaemia, osteomyelitis, prolonged electrocardiogram QT, fluid overload, hyperkalaemia, hypertension, and hypotension 
(all n=2). No adverse event of grade 3 or higher was considered by the site investigators to be treatment related. 
Three participants (5%, 95% CI 0–11) discontinued treatment because of adverse events; one of these (grade 1 allergic 
pruritus) was considered treatment related. Treatment-related adverse events were reported for six individuals (11%, 
95% CI 3–19), the most common of which was nausea (in four individuals [7%]); all treatment-related adverse events 
were grade 1 or 2 in severity.
Interpretation At 48 weeks, switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide was well tolerated. This regimen might provide a tolerable and convenient option for ongoing treatment 
of HIV-1 infection in adults with end-stage renal disease on chronic haemodialysis.
Funding Gilead Sciences.
Introduction
Currently available antiretroviral drugs are highly 
effective and have thus led to striking improvements in 
survival and disease progression in HIV-1-infected 
individuals. The paradigm of HIV treatment has shifted 
to that of treating HIV-infected individuals with long-
term, chronic illness in an increasingly aging popu-
lation who are at risk for non-AIDS-associated 
comorbidities, such as those of the kidney, bone, and 
liver, and cardiac disease.1–3 Previous analyses4,5 that 
included an age-matched, control cohort noted that 
end-stage renal disease occurred at a younger age 
in HIV-1-infected individuals than in HIV-negative 
controls.4,5 Given the prevalence of end-stage renal 
disease in people with HIV and the likelihood that its 
prevalence will increase with the aging of the population 
and the common comorbidities of hypertension and 
diabetes, a safe and convenient antiretroviral regimen 
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is needed for patients with HIV on chronic haemo-
dialysis. However, although kidney transplantation has 
been shown to confer a survival advantage compared 
with remaining on dialysis in HIV-infected individuals,6 
there remain substantial disparities in access to trans-
plantations among black individuals living with HIV in 
the USA, particularly in the south-eastern area, and 
also among ethnic minorities and less-advantaged 
indigenous popu lations in developed countries.7,8
On top of an increased risk of age-related comorbidities, 
individuals with HIV are at risk for acute and chronic 
kidney disease from a wide spectrum of other causes 
including HIV-associated nephropathy, immune complex 
kidney disease, thrombotic microangiopathy, and kidney 
disease associated with comorbidities such as diabetes, 
hypertension, hepatitis B and hepatitis C coinfections, 
and use of medications associated with nephrotoxicity.9,10 
The prevalence of HIV-1 infection in patients with end-
stage renal disease is an estimated 0·5% in Europe11 and 
1·5% in the USA,12 although this might be an under-
estimate of current rates13 since more recent values are 
not available. Furthermore, the prevalence and incidence 
of chronic kidney disease and end-stage renal disease are 
expected to rise as life expectancy improves for people 
living with HIV.14,15 New antiretroviral therapies (ARTs) 
that advance the current standard of care are needed to 
help health-care providers better manage comorbidities 
such as renal disease, since their HIV-1-infected patients 
expect to receive life-long treatment.
Current guidelines recommend initial treatment of 
HIV with a combination of two nucleoside reverse 
transcriptase inhibitors (NRTIs) with a drug from 
another class.16−18 However, most NRTIs are renally 
eliminated,19 which raises concerns for the use of this 
drug class in a population with impaired kidney 
function. As such, ART options for HIV-infected indi-
viduals with chronic kidney disease are few because the 
long-term use of tenofovir disoproxil fumarate has been 
associated with nephro toxicity20 and abacavir has been 
associated with increased cardiovascular risk.21 For 
individuals who cannot be treated with either of these 
drugs, alternative nucleoside-sparing regimens have 
been suggested in treatment guidelines;16−18 how ever, 
this approach is hampered because of con cerns of 
reduced virological activity, drug–drug interactions, 
or tolerability of these combinations.16−18 Additional 
challenges associated with currently available ART regi-
mens in this population also exist, including regimen 
complexity, pill burden (if more than one is needed), 
and risk of dosing errors.22
The NRTI tenofovir alafenamide, a novel prodrug of 
tenofovir, achieves similar antiretroviral efficacy at a 
lower dose than tenofovir disoproxil fumarate, resulting 
in 91% lower plasma tenofovir exposures in individuals 
with normal renal function.23 Several large, phase 3 
studies of HIV-1-infected, treatment-naive and vir-
ologically sup pressed individuals, including those with 
mild-to-moderate renal impairment, have shown long-
term safety and favourable renal and bone profiles with 
tenofovir alafenamide-containing regimens compared 
with those containing tenofovir disoproxil fumarate.24−26 
The single-tablet regimen containing elvitegravir, 
cobicistat, emtricitabine, and tenofovir alafenamide is 
one of the recommended initial regimens in HIV-1 
treatment guidelines in the USA and Europe.16−18 
This regi men can be given without dose adjustment 
to indi viduals with a creatinine clearance as low as 
30 mL/min.27
In this study, we assessed the safety and efficacy of 
switching to a single-tablet regimen of coformulated 
Research in context
Evidence before this study
We searched PubMed for published clinical trials of tenofovir 
alafenamide in patients with HIV-1-infection and renal disease, 
with the title or abstract search terms “tenofovir alafenamide” 
and “HIV” and “study” or “trial” and “renal disease” or “renal 
impairment.” Searches were limited to articles published in 
English between Jan 1, 1997, and March 1, 2018. Our search 
yielded three articles, one of which we excluded because it 
summarised the pharmacokinetics of tenofovir alafenamide in 
individuals without HIV infection and with severe renal 
impairment. The remaining two summarised results at 
weeks 48 and 96, respectively, from an open-label, single-arm 
phase 3 study assessing coformulated elvitegravir, cobicistat, 
emtricitabine, and tenofovir alafenamide in HIV-infected 
adults with a creatinine clearance of 30–69 mL/min. The 
treatment maintained virological suppression and was well 
tolerated in these individuals with mild-to-moderate renal 
impairment.
Added value of this study
This is the first study to assess switching to a single-tablet 
regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide in HIV-infected adults with end-stage renal disease 
on chronic haemodialysis who had been previously maintained 
on a stable antiviral regimen for at least 6 months. The results 
suggested that the single-tablet regimen was well tolerated in 
this patient population through 48 weeks, with maintenance of 
virological suppression and increased patient satisfaction.
Implications of all the available evidence
Convenient, well tolerated treatment options are scarce for the 
growing demographic of HIV-1-infected individuals who have 
an unmet medical need for safer, more convenient antiretroviral 
regimens. The single-tablet regimen of elvitegravir, cobicistat, 
emtricitabine, and tenofovir alafenamide might provide a safe 
and convenient option for ongoing treatment of HIV-1 infection 
in adults with end-stage renal disease on haemodialysis. 
elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide once daily in HIV-1-infected, virologically 
suppressed adults with end-stage renal disease who 
were on chronic haemo dialysis at study entry. Here we 
present the results at 48 weeks.
Methods 
Study design and participants
We did a multicentre, open-label, single-arm, phase 3b 
trial (GS-US-292-1825) at 26 outpatient clinics in 
Austria, France, Germany, and the USA. This study was 
approved by central or site-specific r eview b oards o r 
ethics committees.
Study investigators enrolled HIV-1-infected adults (aged 
at least 18 years) with end-stage renal disease (creatinine 
clearance <15 mL/min) on chronic haemodialysis for at 
least 6 months before screening. Participants were re-
quired to be virologically suppressed (ie, plasma HIV-1 
RNA <50 copies per mL) on a stable antiretroviral regimen 
for at least 6 consecutive months before screening, with a 
CD4 count of at least 200 cells per µL and no documented 
history of HIV resistance to elvitegravir, emtricitabine, 
lamivudine, or tenofovir. All participants provided written 
informed consent. A sub set of participants provided 
additional written, informed consent for a pharmaco-
kinetic substudy. 
Procedures
Eligible participants received a single tablet once daily 
of coformulated elvitegravir 150 mg, cobicistat 150 mg, 
emtricitabine 200 mg, and tenofovir alafenamide 10 mg, 
taken after haemodialysis on dialysis days, for up to 
96 weeks. We undertook post-baseline study visits at 
weeks 2, 4, 8, 12, 24, 36, and 48, and every 12 weeks 
thereafter (up to 96 weeks). Safety was assessed by 
physical examinations, laboratory tests, 12-lead electro-
cardiogram, use of concomitant drugs, and recording 
of adverse events, which were coded using the 
Medical Dictionary for Regulatory Activities (MedDRA, 
version 20.0). Laboratory tests included haematological 
anal ysis, serum chemistry tests, fasting lipid parameters, 
CD4 cell counts, and serum creatinine concentrations to 
measure creatinine clearance (estimated glomerular 
filtration rate by Cockcroft Gault; Covance Laboratories, 
Indianapolis, IN, USA). Blood samples for chemistry 
tests, including serum creatinine, were drawn before 
haemodialysis. Laboratory tests also included measure-
ment of plasma HIV-1 RNA (Roche TaqMan 2.0; Roche 
Diagnostics, Rotkreuz, Switzerland). Protocol-defined 
resistance testing consisted of genotypical and pheno-
typical analysis of integrase, protease, and reverse tran-
scriptase (Monogram Biosciences, South San Francisco, 
CA, USA) for any participant who had a confirmed 
plasma HIV-1 RNA of at least 50 copies per mL with the 
confirmation p lasma H IV-1 R NA a t l east 2 00 c opies 
per mL or who had a plasma HIV-1 RNA of at least 
200 copies per mL in the week 48 window (between 
 
days 295 and 378 [inclusive] of the study), or at the last 
visit on study drug.
The pharmacokinetics of elvitegravir, cobicistat, 
emtricitabine, tenofovir alafenamide, and its active 
metabol ite, tenofovir, were assessed in a dedicated, 
intensive pharmacokinetic substudy. The substudy was 
done at the week 2 or 4 visit after an observed dose on a 
day before haemodialysis and when participants had 
been given three consecutive doses of the single-tablet 
study drug between two haemodialysis sessions to 
assess plasma concentrations of the study-drug 
components at their highest expected concentrations. 
A trough pharmaco kinetic blood sample was obtained 
before administration of an observed dose and intensive 
pharmaco kinetic blood sampling was done post dose at 
0·5, 1, 2, 3, 4, 6, 8, and 24 h. Plasma concentrations 
of elvitegravir, cobicistat, emtricitabine, tenofovir 
alafenamide, and tenofovir were determined using fully 
validated, high-performance liquid chromatography 
tandem-mass spectroscopy bioanalytical methods.
We measured patient-reported outcomes (ie, HIV treat-
ment satisfaction questionnaires [HIV-TSQ], com prising 
the status and change versions) at week 24 and every 
24 weeks thereafter. The HIV-TSQ was administered at 
screening, day 1, and week 4. Medical adherence assess-
ments were done on day 1 and at every post-baseline visit. 
All patient-reported outcome assessments were done at 
the early study drug discontinuation visit.
Outcomes
The primary outcome was the incidence of treatment-
emergent adverse events of grade 3 or higher up to 
week 48. A treatment-emergent grade 3 or higher 
adverse event was defined as a grade 3 or higher adverse 
event with either an onset date on or after the study-
drug start date and no later than 30 days after permanent 
discontinuation of the study drug or one that led to 
premature discontinuation of study drug. Secondary 
outcomes were the incidence of treatment-emergent 
grade 3 or higher adverse events up to week 96, the 
proportion of participants who had plasma HIV-1 RNA 
less than 50 copies per mL at weeks 24, 48, and 96 as 
defined by the US Food and Drug Administration 
(FDA) snapshot algorithm28 for the overall population 
and by subgroups of age, sex, race, geographical region, 
and study-drug adherence rate, the proportion of 
participants who had plasma HIV-1 RNA less than 
20 copies per mL (snapshot algorithm), the proportion 
of participants with plasma HIV-1 RNA less than 
50 copies per mL at week 48 when imputing missing as 
failure and missing as excluded, and the absolute 
change in CD4 cell count and percentage from baseline 
at week 48. Patient-reported outcomes and steady-state 
pharmacokinetic parameters of elvitegravir, cobicistat, 
emtricitabine, tenofovir alafenamide, and tenofovir 
were also determined as secondary outcomes. All 
week 96 outcomes will be reported separately.
Statistical analysis
We did the primary analysis after all enrolled participants 
had completed their week 48 study visit or had pre-
maturely discontinued the study drug. All partici pants 
who were enrolled in the study and received at least 
one dose of study drug (safety analysis set) were 
included in the primary analysis. One planned in-
depend ent data monitoring committee interim analysis 
was done after the first 25 participants enrolled had 
completed their week 12 visit or prematurely dis-
continued the study drug. The independent data 
monitoring committee concluded that efficacy and 
safety findings warranted continuation of the trial. For 
analysis of the primary study endpoint, grade 3 or 
higher adverse events up to the week 48 visit for each 
participant were included. For those who discontinued 
study drug before the week 48 visit, grade 3 or higher 
adverse events up to the last dose date plus 30 days were 
included. The derived 95% CI of the primary endpoint 
was based on normal approximation. A planned sample 
size of 50 participants was based on feasibility and 
considered sufficient to ensure a positive lower bound 
of the primary objective of the study. In a previous 
study,26 the grade 3 or 4 adverse event rate among 
virologically suppressed adults with mild-to-moderate 
renal impairment (creatinine clearance <50 mL/min) 
who switched to elvitegravir, cobicistat, emtricitabine, 
and tenofovir alafenamide was 8·8% at week 48. With 
an assumed rate of grade 3 or higher adverse events of 
10%, 50 participants provided 95% confidence for the 
primary endpoint to be between 1·7% and 18·3%, 
assuming normal approximation to binomial pro-
portions. Other safety data were described using all data 
collected on or after study drug was first given up to 
either the data cutoff date or, for participants who 
discontinued treat ment early, up to 30 days after the last 
dose of study drug.
In the snapshot analysis, participants who were 
enrolled in the study and received at least one dose of 
study drug (full analysis set) were classified in the 
following three outcome groups based on plasma HIV-1 
RNA collected at week 48 while on study treatment: 1) 
plasma HIV-1 RNA less than 50 copies per mL at week 48 
(between days 295 and 378, inclusive); 2) plasma HIV-1 
RNA at least 50 copies per mL, including the following 
three types of participants: plasma HIV-1 RNA at least 
50 copies per mL at week 48; participants who dis-
continued study drug due to reasons other than absence 
of efficacy before or in week 48 with last plasma HIV-1 
RNA at least 50 copies per mL; and participants who 
discontinued study drug before or in week 48 because of 
an absence of efficacy; and 3) no virological data in the 
week 48 window, including for the following two types of 
participants: those who discontinued study drug for 
reasons other than absence of efficacy before or in 
week 48 with last available plasma HIV-1 RNA less than 
50 copies per mL, and participants who were still on 
study drug with missing plasma HIV-1 RNA data at 
week 48. The week 48 efficacy endpoint was also analysed 
by snapshot analysis with a plasma HIV-1 RNA cutoff of 
20 copies per mL, and by analysis of the proportion of 
participants with plasma HIV-1 RNA less than 50 copies 
per mL through imputing the category of no virological 
data as a failure (missing=failure) and as excluded 
(missing=excluded).
Patient-reported outcomes were measured in the safety 
analysis set using the HIV-TSQ, SF-36 (which assesses 
general quality-of life measures), and medication ad-
herence questionnaires. For the medication adherence 
questionnaire, on-treatment data collected up to 1 day 
plus the last dose date of study drug were included in the 
summary. For all other questionnaires, data collected up 
to 30 days plus the last dose date of study drug were 
included in summaries. Multiple responses and out-of-
range responses were set to missing and missing 
responses were not imputed. Study drug adherence was 
computed as the number of pills taken divided by the 
number of pills prescribed (where the number of pills 
taken was the number of pills dispensed minus the 
number of pills returned). We used SAS version 9.4 for 
all analyses. Pharmacokinetic parameters were calculated 
by application of a nonlinear model using standard non-
compartmental analysis (Phoenix WinNonlin version 6.4 
Figure: Trial profile
*Screen failure participants who did not meet the study eligibility criteria might have had more than one criterion that
led to ineligibility. †Among the five participants who met all eligibility criteria but were not enrolled, four withdrew 
consent and one was outside the visit window for their baseline visit.
75 participants screened
55 enrolled and received study drug (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
15 participants did not meet eligibility criteria and were not enrolled* 
9 did not have creatinine clearance <15 mL/min 
2 did not have HIV-1 RNA <50 copies per mL for ≥6 months before screening and HIV-1 RNA <50 copies 
  per mL at screening
2 did not have adequate haematological function (absolute neutrophil count ≥1000 per µL; platelets 
 ≥50 000 per µL; or haemoglobin ≥8·5 g/dL)
2 had an implanted defibrillator or pacemaker
1 had decompensated cirrhosis
4 had CD4 count ≥200 cells per µL
1 had administration of other investigational drugs (ie, participation in any other clinical trial, including 
 observational trials, without previous approval from the sponsor) 
1 confirmed pregnant by a positive serum pregnancy test and who was of child-bearing potential
5 participants met all eligibility criteria but were not enrolled†
43 treatment ongoing at week 48
12 prematurely discontinued from treatment
3 adverse events
1 no efficacy 
2 at investigator’s discretion
1 non-compliance with study drug 
5 participant’s decision 
[Certara USA, Princeton, NJ, USA]). This study is 
registered with ClinicalTrials.gov, number NCT02600819.
Role of the funding source
The funder of the study had the lead role in study 
design, data collection, data analysis, data interpretation, 
and (along with JJEJ) writing of the manuscript. The 
corresponding author had full access to all the data in 
the study and had final responsibility for the decision to 
submit for publication.
Results
Between Dec 15, 2015, and Nov 3, 2016, we screened 
75 participants, and between Feb 1, and Nov 3, 2016, 
55 were enrolled and received at least one dose of study 
drug (figure). M ost p articipants w ere m ale a nd b lack, 
with a median age of 51 years (table 1). Baseline 
characteristics also reflected a  h igh p rominence o f 
comorbidities (eg, diabetes, hypertension, cardiovascular 
disease, and hyperlipidaemia). 
Treatment-emergent grade 3 or higher adverse events 
at week 48 were reported for 18 of 55 participants (33%, 
95% CI 20–45; table 2, appendix pp 2–12). No grade 3 or 
higher adverse event was considered by the site investi-
gator to be treatment related. Treatment-emergent 
grade 3 or higher adverse events that occurred in more 
than one participant included anaemia, osteomyelitis, 
pro longed electrocardiogram QT, fluid overload, hyper-
kalaemia, hypertension, and hypotension (all n=2). 
Although not considered to be treatment related, 
three events (grade 4 generalised oedema, grade 3 pre-
scheduled renal transplant, and grade 1 pruritus allergic) 
led to premature discontinuation of study drug.
Overall, treatment with elvitegravir, cobicistat, 
emtricitabine, and tenofovir alafenamide was well 
tolerated, with most adverse events reported as mild or 
moderate in severity. Adverse events leading to study 
drug discontinuation were uncommon, occurring in 
three of 55 participants (5%, 95% CI 0–11) and included 
grade 4 generalised oedema (n=1), grade 3 scheduled 
renal transplant (n=1), and grade 1 allergic pruritus 
(n=1); only the pruritus event was considered to be 
related to study drug. Treatment-related adverse events 
were reported for six individuals (11%, 95% CI 3–19 
which included nausea [n=4]), and diarrhoea, dyspepsia, 
asthenia, myalgia, polyuria, and allergic pruritus 
(n=1 each). One individual died from heart failure and 
anasarca following staphylococcal endocarditis, events 
that were not considered related to study drug.
For adverse events potentially associated with 
emtricitabine based on previous studies (ie, among 
those listed in the prescribing information as having an 
incidence of at least 10%) regardless of investigator 
attribution, the most commonly reported were grade 1 
or 2 nausea, cough, and diarrhoea. Adverse events in 
this category considered related to study drug were 
reported for five participants (9%); most related events 
were grade 1 or 2. None of these events led to premature 
discontinuation of study drug. The most common 
event, occurring in four of these five participants, was 
grade 1 or 2 nausea.
No clinically relevant changes occurred from baseline 
in median values for haematology or clinical chemistry 
parameters. Creatinine clearance remained stable 
through out the study, with a median (IQR) change 
from baseline at week 48 of 0·1 mL/min (–1·9 to 1·8). 
Overall, 24 participants (44%) had grade 3 or 4 












Body-mass index (kg per m2) 26·3 (23·5–30·4)
Creatinine clearance (mL/min) 10·9 (8·8–13·8)
Duration of haemodialysis (years) 6 (4–10)
HIV-1 RNA <50 copies per mL 54 (98%)





Symptomatic HIV infection 2 (4%)
AIDS 10 (19%)
Mode of infection
Heterosexual sex 33 (60%)
Men who have sex with men 15 (27%)
Intravenous drug use 3 (5%)
Blood transfusion 3 (5%)
Vertical transmission 3 (5%)
Other 1 (2%)
Unknown 3 (5%)
Medication used before antiretroviral switch
Containing tenofovir disoproxil fumarate 16 (29%)
Containing abacavir 31 (56%)
Containing neither tenofovir disoproxil 
fumarate or abacavir
10 (18%)




Cardiovascular disease 26 (47%)
Hyperlipidaemia 23 (42%)
Data are n (%) or median (IQR) except where noted otherwise.
Table 1: Baseline demographic and clinical characteristics
See Online for appendix
was in creased amylase (n=9 [16%] of 55; appendix p 13). 
As is characteristic for individuals with end-stage renal 
disease, median values greater than reference values 
occurred at baseline and post baseline for creatinine, 
blood urea nitrogen, phosphate, parathyroid hormone, 
and amylase; otherwise, median values were generally 
within the relevant reference ranges. Median (IQR) 
change in amylase from baseline at week 48 was –2 U/L 
(–36 to 21). There were no clinically relevant changes 
from baseline in median fasting values for total 
cholesterol, direct LDL cholesterol, HDL cholesterol, 
total cholesterol to HDL ratio, triglycerides, or glucose 
in serum at week 48 (appendix p 14).
In the subset of individuals (n=12) who participated in 
the intensive pharmacokinetic substudy, the measure-
ments of plasma concentrations of elvitegravir, cobicistat, 
emtricitabine, tenofovir alafenamide, and tenofovir were 
taken when concentrations of the renally eliminated drug 
components would be expected to be highest (ie, on a day 
before haemodialysis, after three doses in between 
two dialysis sessions). Exposures of elvitegravir, cobicistat, 
and tenofovir alafenamide, which are metabolised 
through the liver, were consistent with the range of 
historical data in HIV-1 infected adults with normal renal 
function (table 3).27,29 As expected, given that tenofovir and 
emtricitabine are renally eliminated, mean exposures 
(area under the concentration curve [AUC]) of these 
analytes in individuals on haemodialysis were higher than 
historical data obtained following the administration 
of elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide to HIV-1-infected adults with normal renal 
function or with mild-to-moderate renal impairment 
(table 3, appendix p 16). In comparison, tenofovir and 
emtricitabine exposures (AUC0–48h for tenofovir and AUCinf 
for emtricitabine) following single-dose administration of 
tenofovir disoproxil fumarate 300 mg or emtricitabine 
200 mg in adults on haemodialysis treated in previous 
studies were 44 900 and 53 200 ng·h/mL, respectively 
(appendix p 16). Based on these data, these exposures are 
anticipated in individuals on haemodialysis dosed once 
weekly with tenofovir disoproxil fumarate, and once every 
4 days with emtricitabine.
45 participants (81·8%) had plasma HIV-1 RNA less 
than 50 copies per mL at week 48 by the snapshot 
algorithm (table 4). Of the remaining ten participants, 
one had plasma HIV-1 RNA of at least 50 copies per mL 
within the week 48 visit window and subsequently re-
supressed. Another was found after enrolment to have 
pre-existing resistance to emtricitabine (Met184Val) 
and elvitegravir (Gly140Ser, Gln148His) and developed 
treatment-emergent resistance to tenofovir (Lys65Arg) 
while on study. He was therefore discontinued from 
study drug because of absence of efficacy. This participant 
later resuppressed on dolutegravir plus cobicistat-
boosted darunavir. Of the other eight participants, seven 
had no virological data in the corresponding window 
because they had prematurely discontinued study drug 
for reasons other than efficacy, with their last HIV-1 RNA 
value less than 50 copies per mL. Reasons for premature 
discontinuation included adverse events, loss to follow-
up, non-compliance, and protocol violation. The last 
participant was missing data during the week 48 window, 
but was still on study drug and remained suppressed at 
subsequent timepoints. When data were analysed 
imputing the category of no virological data as excluded, 
nearly all participants had plasma HIV-1 RNA less than 
50 copies per mL at week 48 (table 4).
Results from the missing=failure analysis were con-
sistent with the snapshot analysis (table 4). Efficacy was 
similar among subgroups (appendix p 15). Using the 
lower plasma HIV-1 RNA threshold of less than 20 copies 
per mL, the proportion of participants meeting this 





Grade 3 or higher adverse event by week 48 18 (33%)
Grade 3 adverse events 14 (25%)
Grade 4 adverse events 4 (7%)
Any adverse event 51 (93%)





Serious adverse events 29 (53%)
Study drug-related adverse events* 6 (11%)
Study drug-related serious adverse event 0




Any common adverse event associated with 
emtricitabine§
25 (45%)
Grade 1 or 2 24 (44%)
Grade 3 1 (2%)¶
Grade 4 0







Data are n (%). All adverse events up to data cut were included, except for the 
primary endpoint of grade 3 or 4 adverse events, which included adverse events 
up to the week 48 visit for each participant. *Most common study drug-related 
adverse event was nausea (n=4; 7%). †Adverse events leading to study drug 
discontinuation included generalised oedema (n=1), allergic pruritus (n=1), 
and renal transplantation (n=1). ‡Cause of death was heart failure and anasarca 
following staphylococcal endocarditis (n=1). §Common adverse events (≥10%) in 
emtricitabine prescribing information.28 ¶Grade 3 dizziness.
Table 2: Adverse events
81·8%. CD4 cell counts and CD4 percentages remained 
stable through week 48. The median (IQR) change in 
CD4 count from baseline at week 48 was –17 cells per µL 
(–108 to 88), and the median (IQR) change in CD4 
percentage from baseline at week 48 was 1·4% (0·9–4·3). 
As measured with the HIV-TSQ at week 48, 78% of 
participants felt much more satisfied overall with 
elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide compared with their pre-switch baseline 
regimens and 82% were much more satisfied with the 
convenience of taking a single-tablet regimen (appendix 
pp 17–37). Mean adherence at all post-baseline visits 
through week 48 was more than 93% as measured using 
a visual analogue score and more than 96% as measured 
by pill count (appendix pp 38–39). 
Discussion
At 48 weeks, switching to the single-tablet regimen of 
coformulated elvitegravir, cobicistat, emtricitabine, and 
tenofovir alafenamide in HIV-1-infected adults with 
end-stage renal disease on chronic haemodialysis was 
well tolerated, as evidenced by an overall low incidence 
of adverse events that were considered to be treatment 
related or that led to early discontinuation of study 
drug, with maintenance of virological suppression. 
This was the first clinical trial to assess the safety and 
efficacy of switching to a daily single-tablet regimen in 
this patient population. The frequency of treatment-
emergent grade 3 or higher adverse events in our study 
up to week 48 (the primary endpoint) was substantially 
higher than would be expected in a study of otherwise 
healthy adults living with HIV. However, our results 
were not unexpected in a population of HIV-infected 
adults on dialysis for a median of 6 years, nearly 
all of whom had hypertension, approximately half 
had cardiovascular disease or hyperlipidaemia, and a 
quarter had diabetes.
We detected no pattern to the actual distribution and 
types of treatment-emergent grade 3 or higher adverse 
events that were reported, because no event occurred in 
more than two participants. Indeed, the grade 3 or higher 
adverse events were primarily driven by complications or 
related to the above pre-existing medical conditions. We 
found it encouraging that none of the grade 3 or higher 
adverse events in our study were considered treatment 
related, though we acknowledge that there might be 
ascertainment bias in an open-label study. We note that 
our assumed 10% rate of grade 3 or higher adverse events 
was based on a previous study in adults with mild-to-
moderate renal impairment, who were generally in better 
health at baseline than the individuals our current study. 
Therefore, it is reasonable to observe a higher than 
assumed grade 3 or higher adverse event rate in our 
current study.
Not unexpectedly, given the medically complex study 
population with underlying end-stage renal disease, 
most participants had at least one adverse event overall, 
the most common of which were nausea, hyperkalaemia, 
and pneumonia. Nausea and hyperkalaemia are common 
in patients undergoing chronic haemodialysis, and no 
instances of pneumonia were considered related to study 
drug. Overall, the adverse event profile observed was 
consistent with that expected for this study population, 
and the types and frequencies of adverse events reported 
in the current study were consistent with those reported 
in the product information for the elvitegravir, cobicistat, 
emtricitabine, and tenofovir alafenamide single-tablet 
regimen.27 Because emtricitabine is renally eliminated 
and its exposures had previously been observed to be 
increased in adults with mild-to-moderate renal impair-
ment,26 analysis of adverse events potentially associated 
with emtricitabine (ie, among those listed in the 
prescribing information as having at least 10% incidence), 
was carried out separately. The overall incidence of these 
prespecified events occurred in nearly half of study 
participants; however, those events considered related to 
study drug were reported for less than 10%, all were 
grade 1 or 2 in severity, and none led to premature 
discontinuation of study drug. The high overall incidence 
was again not unexpected in our population. These 
End-stage renal disease Healthy renal function
N Mean (percentage 
coefficient of 
variation)




AUCtau (h·ng/mL) 10 14 300 (55%) 19 22 800 (35%)
Cmax (ng/mL) 12 1260 (55%) 19 2110 (34%)
Ctau (ng/mL) 10 174 (60%) 19 287 (62%)
Cobicistat
AUCtau (h·ng/mL) 11 10 200 (59%) 19 9460 (34%)
Cmax (ng/mL) 12 1370 (67%) 19 1450 (28%)
Ctau (ng/mL) 10 28·9 (118%) 19 20·6 (85%)
Emtricitabine
AUCtau (h·ng/mL) 11 62 900 (48%) 19 11 700 (17%)
Cmax (ng/mL) 12 4880 (41%) 19 2060 (20%)
Ctau (ng/mL) 10 1280 (59%) 19 952 (47%)
Tenofovir alafenamide
AUClast (h·ng/mL) 12 232 (53%) 19 228 (47%)
Cmax (ng/mL) 12 246 (75%) 19 233 (65%)
Tenofovir
AUCtau (h·ng/mL) 10 8720 (39%) 19 326 (15%)
Cmax (ng/mL) 12 443 (41%) 19 182 (12%)
Ctau (ng/mL) 10 265 (73%) 19 114 (18%)
Data obtained from participants in this study with end-stage renal disease or healthy renal function in historical 
controls from intensive pharmacokinetic analysis in a phase 2 trial with HIV-infected adults.29 AUCtau=area under the 
concentration versus time curve over the dosing interval. Cmax=maximum observed concentration of drug. 
Ctau=observed drug concentration at the end of the dosing interval. Tmax=time (observed time point) of Cmax. t1/2=estimate 
of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination 
rate constant (λz). AUCtau=area under the concentration versus time curve from time 0 to the last measureable 
concentration. 
Table 3: Steady-state plasma pharmacokinetic parameters in adults with end-stage renal disease or 
healthy renal function
observations support the safety of emtricitabine at a dose 
of 200 mg daily in the single-tablet regimen of elvitegravir, 
cobicistat, emtricitabine, and tenofovir alafenamide with-
out dose adjustment in adults with minimal residual 
renal function undergoing haemodialysis. Study drug-
related adverse events were reported for few participants 
overall, despite the fact that participants were switched in 
an unmasked manner to a new combination.
Exposures of tenofovir alafenamide and cobicistat in 
adults on haemodialysis in our study were consistent 
with historical data in HIV-infected individuals with 
healthy renal function. Although the mean steady-state 
plasma exposures of elvitegravir in participants on 
haemodialysis in our study were numerically lower than 
in those with normal renal function in previous studies, 
these exposures were within the safe and efficacious 
ranges of other phase 3 trials in HIV-1-infected adults 
with healthy renal function, and are supported by the 
safety and efficacy results of this study. Although the 
plasma concentrations of tenofovir and emtricitabine 
were increased in the population on haemodialysis 
compared with historical data in HIV-1-infected 
adults with healthy renal function and mild-to-moderate 
renal impairment receiving coformulated elvitegravir, 
cobicistat, emtricitabine, and tenofovir alafenamide, the 
overall safety profile was not substantially affected. All 
participants were expected to have limited or no residual 
renal function given that they had been on haemodialysis 
for extended periods of time. Moreover, exposures of 
tenofovir within this study were less than those in adults 
on haemodialysis who had received tenofovir disoproxil 
fumarate.30
Finally, switching to elvitegravir, cobicistat, emtricitabine, 
and tenofovir alafenamide maintained high rates of 
virological suppression, with treatment-emergent re-
sistance in only one participant who retrospectively was 
found to have pre-existing resistance at baseline. HIV 
treatment satisfaction was also improved from baseline, 
reflecting how simplification to a single-tablet regimen 
offers a once-daily option for individuals on chronic 
haemodialysis who often have complicated HIV dosing 
schedules, multiple comorbidities, and a high pill burden.
Our trial population included individuals with end-stage 
renal disease who were enrolled at international sites where 
management of this condition might vary. There were also 
substantial proportions of women and black participants by 
contrast with other studies of new drugs for initial or switch 
therapies.24–26,31,32 A potential limitation of our small, open-
label, single-arm study (ie, with no control group) in 
a patient population with multiple comorbidities is the 
reduced ability to distinguish back ground and study drug-
related adverse events. However, given the expected high 
background adverse event rate in this population, the few 
discontinuations due to study drug-related adverse events 
was reassuring. We analysed the primary outcome after 
48 weeks of treatment and did not detect serious safety 
signals; however, analysis of follow-up safety data through 
96 weeks will be important and is ongoing. We did not 
assess residual renal function using more specific 
measures such as 24 h timed blood and urine urea or 
creatinine collection peridialysis, and we did not do bone 
densitometry studies within our single-arm study. Although 
tenofovir alafenamide in HIV-infected individuals with 
mild-to-moderate renal impairment has been shown to be 
safe for bone, this has not been studied in individuals on 
dialysis and is an important aim for future investigation. In 
individuals on haemodialysis who are awaiting a trans-
plantation, a regimen containing cobicistat might not be 
ideal because of the potential drug–drug interactions. 
Other tenofovir alafenamide-containing regimens should 
be investigated within this setting. Finally, although 
tenofovir alafenamide and emtricitabine have low potential 
Elvitegravir, cobicistat, 
emtricitabine, and tenofovir 
alafenamide (n=55)
Week 24
HIV-1 RNA <50 copies per mL 48 (87·3%, 75·5–94·7)*
HIV-1 RNA ≥50 copies per mL 1 (1·8%, 0–9·7)*
HIV-1 RNA ≥50 copies per mL in week 24 window 0
Discontinued study drug because of no efficacy 1 (1·8%)
Discontinued study drug because of adverse event or death and last 
available HIV-1 RNA ≥50 copies per mL
0
Discontinued study drug for other reasons† and last available HIV-1 RNA 
≥50 copies per mL
0
No virological data in week 24 window 6 (10·9%)
Discontinued study drug because of adverse event or death and last 
available HIV-1 RNA <50 copies per mL
2 (3·6%)
Discontinued study drug for other reasons† and last available HIV-1 RNA 
<50 copies per mL
4 (7·3%)
Missing data during window but on study drug 0
Week 48
HIV-1 RNA <50 copies per mL 45 (81·8%, 69·1–90·9)*
HIV-1 RNA ≥50 copies per mL 2 (3.6%, 0·4–12·5)*
HIV-1 RNA ≥50 copies per mL in week 48 window 1 (1·8%)
Discontinued study drug because of no efficacy 1 (1·8%)
Discontinued study drug because of adverse event or death and last 
available HIV-1 RNA ≥50 copies per mL
0
Discontinued study drug for other reasons† and last available HIV-1 RNA 
≥50 copies per mL
0
No virological data in week 48 window 8 (14·5%)
Discontinued study drug because of adverse event or death and last 
available HIV-1 RNA <50 copies per mL
2 (3·6%)
Discontinued study drug for other reasons† and last available HIV-1 RNA 
<50 copies per mL
5 (9·1%)
Missing data during window but on study drug 1 (1·8%)
HIV-1 RNA <50 copies per mL by missing=failure analysis‡ 46/55 (83·6%, 71·2–92·2)*
HIV-1 RNA <50 copies per mL by missing=excluded analysis§ 46/47 (97·9%, 88·7–99·9)*
Data are n (%, 95% CI) or n (%). *95% CIs were obtained using the exact method. †Other reasons included participants 
who discontinued study drug because of investigator’s discretion, participant’s decision, loss to follow-up, 
non-compliance with study drug, protocol violation, pregnancy, or study terminated by sponsor. ‡The denominator 
for percentages was the number of participants in the full analysis set. §The denominator for percentages was the 
number of participants in the full analysis set with non-missing HIV-1 RNA at each visit.
Table 4: Virological outcomes at weeks 24 and 48
for mitochondrial toxicity compared with other nucleoside 
analogues, further follow-up is required to assess long-
term safety in this patient population.33,34
Results from our study reinforce the large body of 
evidence showing that tenofovir alafenamide-con taining 
regimens could be used in individuals with varying 
degrees of renal impairment. Multiple studies in 
treatment-naive individuals have shown significant 
differ ences in renal safety parameters between tenofovir 
alafenamide and tenofovir disoproxil fumarate, and 
virologically suppressed adults with normal to moder-
ately impaired renal function (ie, creatinine clearance 
≥30 mL/min) who switched to tenofovir alafenamide 
from tenofovir disoproxil fumarate had significant 
improve ments in total and tubular proteinuria. More-
over, large phase 3 studies of regimens containing the 
emtricitabine and tenofovir alafenamide NTRI back-
bone have shown no differences in renal or bone safety 
compared with that of regimens containing abacavir 
and lamivudine in participants with normal to moder-
ately impaired renal function (ie, creatinine clearance 
≥50 mL/min).25,31
In conclusion, these results support the use of 
the single-tablet regimen of elvitegravir, cobicistat, 
emtricitabine, and tenofovir alafenamide once daily for 
the treatment of HIV-1 infection in adults with end-stage 
renal disease on chronic haemodialysis with minimal 
residual renal function. This regimen might provide a 
tolerable and convenient option for ongoing treatment 
of HIV-1 infection in this population and could reduce 
pill burden and the potential for dosing errors.
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